US FDA approves Gilead's twice-yearly injection for HIV prevention

FDA approves Gilead Sciences' GILD.O lenacapavir, a twice-yearly injection, under the brand name Yeztugo, for preventing HIV infection in adults and adolescents

J.P. Morgan expects a "fairly rapid uptake for lenacapavir, particularly as we get into 2026"

"For U.S. sales, we forecast Yeztugo PrEP revenues of $85 million in 2025, growing to $400 million in 2026 and $3 billion by 2030" - J.P.Morgan

Brokerage sees the potential for less frequent testing requirements being well received by physicians and users

"The opportunity for Lenacapavir is large, but it will take time for the market transition to occur," says BMO Capital Markets in a note

As of last close, stock up 17.04% YTD